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The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to
initial breast-conserving surgery. This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant
chemotherapy. Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas
were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation
(surgery and/or radiotherapy) or mastectomy. Median follow-up was 10 years. Clinical response to primary chemotherapy was
significantly worse for lobular than for ductal carcinomas (47 vs 60%; P¼0.04), but only histological grade remained predictive in
multivariate analysis. Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P¼0.07), due, in part, to the
use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients. The lobular type had no adverse effect,
neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.
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The standard treatment of operable breast adenocarcinomas too
large to be amenable to breast-conserving surgery is mastectomy
with axillary lymph node clearance. Several randomised studies
have compared neoadjuvant with adjuvant chemotherapy. In these
studies, the locoregional treatment could be either surgery or
radiotherapy or a combination of both. There was no significant
difference in terms of locoregional control and overall (OS) or
disease-free survivals (Mauri et al, 2005). The principal clinical
benefit of a neoadjuvant medical treatment was, in the case of good
clinical response, avoiding mastectomy. However, data regarding
the specific behaviour of invasive lobular carcinomas (ILC), a
histological subtype of breast cancers representing 5–15% of all
breast cancer cases, are still scarce in this therapeutic setting.
Lobular carcinomas are characterised by a specific morphology
with discohesive small cells usually associated with estradiol
receptor (ER), progesterone receptor (PR) positivity and with a
low proliferation rate (Sastre-Garau et al, 1996). These factors are
now well-established predictive markers of poor response to
neoadjuvant chemotherapy (Pierga et al, 2003). We, and others,
have previously shown that ILC are often diagnosed as larger
tumours than invasive ductal carcinomas (IDC) (Sastre-Garau
et al, 1996), and for which a neoadjuvant treatment could be
chosen to increase the rate of conservative surgery. This study
aims to compare the outcome of lobular vs ductal carcinomas
under neoadjuvant chemotherapy and to report their locoregional
control.
MATERIALS AND METHODS
Between January 1989 and December 1999, a total of 803 patients,
with operable, clinical stage II/IIIA, either ductal or lobular
invasive breast carcinoma, not amenable to initial breast-conser-
ving surgery, were treated at the Institut Curie with primary
chemotherapy. Out of them, 750 had an initial core-needle biopsy
before the start of treatment and will be studied here – 78 patients
with lobular invasive carcinoma and 672 with ductal invasive
carcinomas. The other 53 had initial fine-needle aspiration and
underwent biopsy after the start of the chemotherapy. Median
follow-up was 117 months (10–188). Histological classification
was made according to the WHO criteria. Histological grading
was performed according to the Scarff Bloom and Richardson
method (Bloom and Richardson, 1957). Positivity to ER and PR
was determined by biochemistry. Hormonal receptors (HR) were
considered positive when either ER or PR was positive. All slides of
lobular carcinomas were retrospectively reviewed. The E-cadherin
expression was assessed by immunohistochemistry.
Treatment decisions were not adapted to the histological type.
The following information regarding the treatment details apply
both to lobular and ductal carcinomas. No patient received
neoadjuvant hormonal therapy. All patients received a median
of four (range: 1–6) cycles of neoadjuvant chemotherapy.
Chemotherapy between 1989 and 1995, consisted of FAC with
5-Fluorouracil (F) on days 1, 3, 5 and 8, adriamycin (A) on days 1
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sand 8, and cyclophosphamide (C) on days 1 and 8 (Pierga et al,
2003). It was subsequently simplified according to a more classical
regimen with adriamycin or epirubicin (E), cyclophosphamide
and/or fluorouracil every 21 days for six cycles (FAC, FEC, AC or
EC) (French Adjuvant Study Group, 2001).
Response to primary chemotherapy was assessed clinically as
reported by Pierga et al (2003), according to the International
Union against Cancer Criteria. Complete response was defined as
the total resolution of the breast mass and regional lymph
adenopathy as determined by physical examination; partial
response was defined as 50% or greater reduction in the product
of the two largest perpendicular dimensions of the breast mass and
regional adenopathy; minor response was defined as less than a
50% reduction in the product of the two largest perpendicular
dimensions. Stable disease was defined as no measurable change in
the product of the two largest perpendicular dimensions, and
progressive disease was defined as an increase of at least 25% in
the product of the two largest perpendicular dimensions. Clinical
response was dichotomised in two groups: o50 and X50%.
Local treatments consisted in breast surgery and/or radio-
therapy. Whenever feasible, it consisted in tumorectomy followed
by radiotherapy. When the tumour did not become amenable to
conservative surgery, the decision was usually made to perform a
mastectomy, followed in most cases by radiotherapy. However,
some patients, because of a desire to conserve their breasts,
received radiotherapy as first (followed by either tumorectomy or
mastectomy) or exclusive local treatment. In other instances, this
sequence of preoperative or exclusive radiotherapy was chosen for
tumours with very good response to chemotherapy. Radiotherapy
delivered a mean dose of 51.4Gy (s.d. 2.5Gy) in 2Gy fractions to
the breast, using either standard or lateral decubitus techniques
(Campana et al, 2005), or to the chest wall. A mean dose of 45Gy
(s.d., 2Gy) in 23–25 fractions was usually delivered to the internal
mammary chain and the supraclavicular area with the addition
of an axillary irradiation when there was an important axillary
involvement or in the absence of an axillary lymph node
dissection. In the case of breast–conserving treatments, a boost
was delivered to the tumour or to the tumorectomy bed by either
external beam radiotherapy or brachytherapy. The mean total dose
was 64Gy (s.d., 7.6Gy) to the tumorectomy bed for postoperative
radiotherapy and 73Gy (s.d., 7.6Gy) to the tumour in the case of
exclusive radiotherapy. Patients were followed up clinically every 6
months for the first 5 years and annually thereafter. Mammograms
and/or ultrasound scans were performed annually.
Statistics
All studied factors are reported in the relevant Tables.
Differences between groups were analysed by w
2 tests for
categorical variables and Student’s t-test for continuous variables.
Univariate logistic regressions were performed to identify
predictive factors of clinical response (X50%) and to estimate
crude odds ratios (OR). Multivariate logistic regression analyses
permitted to estimate the OR of variables independently associated
with clinical response.
Survival data were defined as the time from diagnosis of breast
cancer until the occurrence of event, that is, locoregional
recurrence (LRR) defined as any recurrence occurring in the
treated breast or in the ipsilateral chest wall or regional lymph
node-bearing areas (internal mammary chain, axilla and supra-
clavicular area) and death (OS). Recurrence-free and alive patients
were censored at the date of their last known contact. The OS and
LRR rates were calculated by the Kaplan–Meier method, and
groups were compared using a log-rank test. Multivariate analysis
was carried out to assess the relative influence of prognostic
factors on locoregional control, using the Cox stepwise procedure
after stratification on the local treatment (exclusive/preoperative
radiotherapy vs postoperative radiotherapy) (Cox and Oakes,
1984). Missing values (tumour grade, receptor levels and mitotic
index) were coded as separate categories of the variable and
retained in the model.
Significance level was 0.05. Analyses were performed using Splus
2000 software (Mathsoft Inc., Seattle, WA, USA).
Table 1 Tumour and treatment characteristics according to the
histological type of the invasive breast carcinoma
Ductal (N¼672) Lobular (N¼78)
Total N % N % P
Age (DM¼0) o10
 2
Median (min–max) in years 46 (24–70) 49 (39–68)
Menopause (DM¼0) 0.88
Yes 167 25 20 26
No 505 75 58 74
Clinical T stage (DM¼0) 0.03
T2 506 75 50 64
T3 166 25 28 36
Clinical N stage (DM¼0) 0.16
N0 411 61 54 69
N1 261 39 24 31
Tumour clinical maximal diameter (DM¼0) o10
 3
Median (min–max) in mm 40 (20–70) 50 (25–70)
Histological grade (DM¼4)
a o10
 3
18 2 1 2 3 2 4 1
2 332 50 30 38
3 210 31 7 9
Mitoses per 10 HPF (DM¼72) o10
 3
(0–10) 129 21 53 80
(11–21) 182 30 7 11
X22 291 48 6 9
Hormonal receptors (DM¼118) 0.02
ER+ and/or PR+ 412 73 54 87
ER /PR  158 28 8 13
HPF¼high-power field; DM¼data missing. Menopause defined, for women with
intact uterus, as 2 years of amenorrhea and for the others, biologically. Percentages
were rounded, so, when added, the sum may not be exactly 100.
aFifty-three
tumours (44 ductal and 9 lobular) could not be evaluated.
Table 2 Clinical responses to neoadjuvant chemotherapy
Ductal (N¼672) Lobular (N¼78)
Total N % N % P
Clinical response to primary chemotherapy (DM¼7) 0.04
X50% 397 60 37 47
o50% 268 40 41 53
Local treatment (DM¼0) 0.01
Tumorectomy followed by RT 292 43 16 21
Mastectomy followed by RT 160 24 25 32
Mastectomy alone 42 6 6 8
RT followed by tumorectomy 45 7 8 10
RT followed by mastectomy 36 5 5 6
RT alone 97 14 18 23
DM¼data missing; RT, radiorherapy. Local treatments. Percentages were rounded,
so, when added, the sum may not be exactly 100.
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sRESULTS
Patients’ and tumours’ characteristics according to the
histological type of invasive carcinoma
The comparison of the 78 patients with lobular invasive carcinoma
with the 672 with ductal invasive carcinomas is summarised in
Table 1.
Patients diagnosed with lobular invasive carcinomas were
significantly older than patients with ductal carcinomas. Lobular
cancers were significantly larger (median size of 50 vs 40mm;
Po10
 3) with more HRs positive (HRþ;8 7vs 73%; P¼0.02) and
lower histological grades than ductal carcinomas (grade 1; 41 vs
12%; Po10
 3).
Response to primary chemotherapy and local treatment
according to histological type
Clinical response to primary chemotherapy was significantly better
for ductal invasive carcinomas than for lobular (X50% of clinical
response in 60% for ductal vs 47% for lobular; P¼0.04; Table 2).
The rates of breast-conserving treatments for lobular carcinomas
was lower than that for ductal carcinomas, but the difference was
not statistically significant (54% (42 out of 78) vs 65% (434 out of
672); P¼0.07) and more patients with lobular carcinomas received
local treatment with either exclusive radiotherapy or preoperative
radiotherapy compared with ductal carcinomas (40 (31 out of 78)
vs 26% (178 out of 672); P¼0.02). If we look at patients who had
surgery, excluding patients with radiotherapy alone as local
treatment, there were significantly fewer breast conservations for
lobular than for ductal invasive carcinomas: 24 out of 78 (31%) vs
333 out of 672 (50%), P¼0.001. Rates of pathological complete
response (for all patients who had undergone surgery) were
respectively 9% (40 out of 457, 118 unknown) for ductal and 8%
(4 out of 50, 10 unknown) for lobular (P¼0.94).
Table 3 Predictive factors of clinical response (450%) according to
univariate and multivariate analyses
Univariate analysis Multivariate analysis
N CR (%) P RR (IC 95%) P RR (IC 95%)
Age
440 548 58 1
p40 138 55 0.6 0.9 (0.6–1.3)
Menopause
No 512 56
Yes 174 61 0.3 1.2 (0.8–1.7)
Clinical tumour stage
cT2 515 60
cT3 171 51 o0.05
a 0.7 (0.5–0.99) 0.12 0.7 (0.5–1.1)
Clinical nodal status
cN0 425 56
cN1 261 60 0.3 1.2 (0.9–1.6)
Histological type
Ductal 617 59
Lobular 69 43 0.02 0.5 (0.3–0.9) 0.23 0.7 (0.4–1.3)
Hormonal receptors
b
HR+ 433 55
HR  144 65 0.03 1.5 (1.0–2.3) 0.09 1.4 (0.9–2.1)
Histological grade
Grade 1 113 42 1 1
Grade 2 360 59 0.003 1.9 (1.3–3.0) 0.02 1.8 (1.1–3.0)
Grade 3 213 63 o10
 3 2.3 (1.4–3.7) 0.02 2.0 (1.1–3.4)
ER¼estradiol receptor; HR¼hormonal receptor; PR¼progesterone receptor.
aFactors entered in the multivariate analysis.
bHR+ if ER+ and/or PR+.
Table 4 Comparison of patients treated with breast conserving treatment with either exclusive/preoperative radiotherapy or postoperative radiotherapy
Exclusive or preoperative radiotherapy (N¼168)
a Postoperative radiotherapy (N¼308)
Total N % N % P
Menopause (DM¼0) 0.44
No 121 72 232 75
Yes 47 28 76 25
Clinical T stage (DM¼0) 0.03
T2 129 77 262 85
T3 39 23 46 15
Clinical N stage (DM¼0) 0.21
N0 105 63 210 68
N1 63 37 98 32
Histological type (DM¼0) o10
 3
Ductal 142 85 292 95
Lobular 26 15 16 5
Clinical response to primary chemotherapy o10
 3
X50% 104 63 239 78
o50% 60 37 67 22
Hormonal receptors (DM¼71) 0.24
ER+ and/or PR+ 99 68 192 74
ER /PR  46 32 68 26
DM¼data missing; ER¼estradiol receptor; HR¼hormonal receptor; PR¼progesterone receptor.
a53 preoperative radiotherapy and 115 exclusive radiotherapy.
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analysis (Table 3) were clinical T2 vs T3, HRþ vs HR  and high
histological grade vs low and intermediate. In multivariate
analysis, only high grade was significantly associated with a higher
rate of clinical response.
Comparison of patients who underwent breast
conservation with either preoperative/exclusive
radiotherapy or postoperative radiotherapy
Among patients who received breast-conserving treatments, those
with preoperative/exclusive radiotherapy had tumours that were
significantly more often clinically T3 (23 vs 15%; P¼0.03), lobular
(15 vs 5%; Po10
 3) and responded clinically less to primary
chemotherapy (clinical response X50% respectively 63 vs 78%;
Po10
 3) than those with postoperative radiotherapy (Table 4).
Survivals
Overall survival rates at, respectively, 5 and 10 years were 81 (95%
CI, 78–84%) and 66% (95% CI, 62–70%).
Locoregional control rates at, respectively, 5 and 10 years were
83 (95% CI, 81–86%) and 75% (95% CI, 71–78%) but, when
considering only patients treated with breast conservation, 81
(95% CI, 77–85%) and 71% (95% CI, 67–76%).
Prognostic factors
For locoregional control In univariate analysis, factors that were
found to be associated with a higher locoregional recurrence rate
were young age, cN1, HR  and having undergone a breast-
conserving treatment (Table 5). The histological subtype classifi-
cation (lobular vs ductal) was not found to be prognostic for
locoregional control, with values at 10 years being 73 and 75%,
respectively (RR¼1 (0.6–1.7); P¼0.9).
On forward stepwise multivariate analysis (Cox model) stratified
on local treatment, only the young age (o40 years) remained
statistically significant.
When considering only patients treated with breast conservation
(Table 6), the only factors found in univariate analysis to be
associated with a higher locoregional recurrence rate were young
age and treatment with preoperative or exclusive radiotherapy.
The histological subtype classification (lobular vs ductal) was not
found to be prognostic for locoregional control with, respectively,
at 10 years, a locoregional control of 62 and 72% (RR¼1.5 (0.9–2.6);
P¼0.12).
Table 5 Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival
Univariate analysis Multivariate analysis
N 10-year LRRFS (%) (IC 95%) P
a RR (IC 95%) P
b RR (IC 95%)
Age (continuous variable) 0.015 0.97 (0.96–1.00)
Age (dummy variable)
c o10
 6 o10
 3
440 597 79 (75–82) 1 1
p40 153 60 (51–70) 2.2 (1.6–3.1) 2.3 (1.6–3.2)
Menopause 0.5
No 563 73 (69–78) 1
Yes 187 79 (73–86) 0.9 (0.6–1.3)
Clinical tumour stage
c 0.35
cT2 556 74 (69–78) 1
cT3 194 78 (72–86) 0.8 (0.6–1.2)
Clinical nodal status
c 0.33
cN0 465 76 (71–80) 1
cN1 285 74 (68–80) 1.2 (0.8–1.6)
Histological type 0.9
Ductal 672 75 (71–79) 1
Lobular 78 73 (62–86) 1 (0.6–1.7)
Hormonal receptors
c 0.05 0.02
HR+ 466 75 (71–80) 1 1
HR  166 69 (62–78) 1.4 (1.0–2.0) 1.7 (1.2–2.5)
Histological grade 0.34
Grade 1 114 82 (75–90) 1
Grade 2 362 73 (68–79) 1.3 (0.8–2.0)
Grade 3 217 73 (67–81) 1.4 (0.9–2.4)
Mitotic index 0.48
Grade 1 182 79 (72–87) 1
Grade 2 189 77 (70–84) 1.2 (0.7–1.9)
Grade 3 297 75 (69–81) 1.3 (0.8–2.0)
Clinical response 0.72
X50% 434 78 (74–83) 1
o50% 309 76 (70–82) 1.1 (0.8–1.5)
HR¼hormonal receptor; LRRFS¼locoregional recurrence-free survival
aLog-rank test.
bLikelihood ratio test.
cFactors entered in the multivariate analysis.
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sOn multivariate analysis (Cox model) stratified on local
treatment, only young age (o40 years) remained statistically
associated with worse locoregional control.
For overall survival In univariate analysis, factors that were
found to be associated with a lower overall survival rate were cT3,
cN1, HR , histological grade 2 and 3 and mitotic index grade 2
and 3 (Table 7). The histological subtype classification (lobular vs
ductal) was not found to be prognostic for overall survival with,
respectively, at 10 years, a rate of 72% (95% CI, 62–84%) and 65%
(95% CI, 61–69); RR¼0.84 (0.55–1.30); P¼0.44.
On forward stepwise multivariate analysis (Cox model) stratified
on local treatment, cT3, cN1, HR , histological grade 2/3 and
absence of clinical response were statistically significant.
DISCUSSION
This retrospective study spans a period of 10 years with patients
treated between 1989 and 1999. The follow-up is long with a
median at 10 years and makes the study of locoregional survival
relevant. The tumour characteristics of lobular carcinomas were
those already found by Sastre and co-workers and others (Sastre-
Garau et al, 1996; Cristofanilli et al, 2005). Patients diagnosed with
lobular invasive carcinomas were significantly older (Sastre-Garau
et al, 1996) than patients with ductal tumours. Lobular cancers
were significantly larger (Sastre-Garau et al, 1996; Cristofanilli
et al, 2005; Tubiana-Hulin et al, 2006) with more HRs (Sastre-
Garau et al, 1996; Mathieu et al, 2004; Cristofanilli et al, 2005;
Tubiana-Hulin et al, 2006) and lower histological (Sastre-Garau
et al, 1996; Tubiana-Hulin et al, 2006) or nuclear (Cristofanilli
et al, 2005; Tubiana-Hulin et al, 2006) grade than ductal
carcinomas.
Because of the frequent use of either exclusive or preoperative
radiotherapy, the study of pathological response in our series was
not relevant. Bearing in mind the mandatory caution in interpret-
ing clinical response (Bollet et al, 2007), we found that the
response to primary chemotherapy was significantly better for
ductal invasive carcinomas than for lobular (X50% of clinical
response in 60% for ductal vs 47% for lobular; P¼0.04),
Table 6 Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival for patients treated by breast conservation
Univariate analysis Multivariate analysis
a
N 10-year LRRFS (%)(IC 95%) P
b RR (IC 95%) P
c RR (IC 95%)
Age (continuous variable) 0.0009 0.96 (0.94–0.98)
Age (dummy variable)
d o10
 6 o10
 5
440 382 77 (72–82) 1 1
p40 94 49 (38–63) 2.6 (1.8–3.7) 2.6 (1.7–3.7)
Menopause
d 0.1
No 353 69 (63–74) 1
Yes 123 80 (73–88) 0.7 (0.4–1.1)
Clinical tumour stage
d 0.81
cT2 391 72 (67–77) 1
cT3 85 71 (60–83) 1.1 (0.7–1.7)
Clinical nodal status
d 0.06
cN0 315 73 (68–79) 1
cN1 161 68 (60–77) 1.4 (1.0–2.1)
Histological type
d 0.12
Ductal 434 72 (68–77) 1
Lobular 42 62 (47–82) 1.5 (0.9–2.6)
Hormonal receptors
d 0.54
HR+ 291 72 (66–78) 1
HR  114 68 (59–79) 1.1 (0.7–1.7)
Histological grade 0.97
Grade 1 71 73 (63–85) 1
Grade 2 215 70 (63–77) 1.0 (0.6–1.6)
Grade 3 156 72 (64–81) 0.9 (0.5–1.6)
Mitotic index 0.72
Grade 1 110 71 (62–83) 1
Grade 2 125 72 (64–82) 1.1 (0.7–1.8)
Grade 3 195 70 (63–78) 1.2 (0.8–1.9)
Clinical response 0.29
X50% 343 74 (69–79) 1
o50% 127 67 (58–77) 1.2 (0.8–1.8)
Locoregional treatment o10
 3
Postop 308 77 (71–83)
Preop/excl 168 61 (53–70) 2.0 (1.4–2.8)
HR¼hormonal receptor; LRRFS¼locoregional recurrence-free survival
aMultivariate analysis after stratification on local treatment.
bLog-rank test.
cLikelihood ratio test.
dFactors
entered in the multivariate analysis. Preop/excl: locoregional treatment consisted in preoperative or exclusive radiotherapy.
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responded less than ductal carcinomas to neoadjuvant chemother-
apy (Mathieu et al, 2004; Cristofanilli et al, 2005; Tubiana-Hulin
et al, 2006; Wenzel et al, 2006; Katz et al, 2007). However, in the
present study, in multivariate analysis, only high grade was
significantly associated with a higher rate of clinical response. This
result is therefore in agreement with the Nomograms’s design
proposed online, which does not take into account the histological
type of the tumour when deciding on the therapeutic option
(Rouzier et al, 2005b). There is room to better define biological
predictive factors of response to neoadjuvant chemotherapy to
screen patients who would benefit most from this therapeutic
option (Sotiriou et al, 2002; Chang et al, 2005; Gianni et al, 2005;
Rouzier et al, 2005a; Pierga et al, 2007). Lobular carcinomas had
reduced clinical responses to neoadjuvant chemotherapy, while
responses to breast-conserving treatments were fewer, although
not significantly (54% (42 out of 78) vs 65% (434 out of 672);
P¼0.07). The lower rate of breast conservation in lobular vs ductal
invasive carcinoma could also be due to the larger size of ILC. The
most striking data are the high rate of breast conservation for both
ductal and even more so for lobular carcinomas when compared to
the rates in the literature that range, respectively, between 30–48
and 16–31% (Mathieu et al, 2004; Cristofanilli et al, 2005;
Tubiana-Hulin et al, 2006). This is explained in our series by the
use of either exclusive or preoperative radiotherapy, particularly
for large tumours with a poor response to neoadjuvant
chemotherapy and, therefore, more frequently for lobular (40%)
than for ductal (26%) carcinomas. Because of the retrospective
nature of this study, we could not report the reason for the choice
of performing preoperative or exclusive radiotherapy. However, as
one can see from Table 2, the proportion of patients who received
radiotherapy immediately after primary chemotherapy and who
actually went on to have successful breast-conserving treatments
was 80 and 84%, respectively, for IDC and ILC.
Despite being associated with large tumour size and less clinical
response to primary chemotherapy, lobular subtype was not found
associated with either worse locoregional control, even in the
subgroup of only patients who had been treated with breast
conservation, or worse overall survival. It should, however, be
noted that in this series, patients treated with exclusive or
preoperative radiotherapy fared worse in terms of locoregional
control than others, perhaps also because of a selection of patients
with poor prognosis. This opens the debate as to whether
radiotherapy could not play a role in increasing the rate of
Table 7 Univariate and multivariate analyses of prognostic factors for overall survival
Univariate analysis Multivariate analysis
N 10-year LRRFS (%)(IC 95%) P RR (IC 95%) P RR (IC 95%)
Age (continuous variable) 0.7 1.0 (0.99–1.02)
Age (dummy variable) 0.11
440 597 67 (63–72) 1
p40 153 60 (52–69) 1.3 (0.9–1.7)
Menopause
a 0.22
No 563 67 (63–72) 1
Yes 187 63 (55–71) 1.2 (0.9–1.6)
Clinical tumour stage
a 0.005
cT2 556 68 (64–73) 1
cT3 194 59 (51–67) 1.5 (1.1–1.9)
Clinical nodal status
a o10
 7 o10
 3
cN0 465 73 (69–78) 1 1
cN1 285 54 (48–61) 2.0 (1.6–2.6) 2.1 (1.6–2.7)
Histological type 0.44
Ductal 672 65 (61–69) 1
Lobular 78 72 (62–84) 0.8 (0.6–1.3)
Hormonal receptors (HR)
a o10
 7 o10
 3
HR+ 466 70 (66–75) 1 1
HR  166 49 (42–58) 2.2 (1.7–2.8) 2.4 (1.8–3.2)
Histological grade
a,b 0.0004 0.02
Grade 1 114 78 (69–87) 1 1
Grade 2 362 66 (61–71) 1.8 (1.1–2.8) 1.8 (1.1–2.8)
Grade 3 217 58 (51–66) 2.5 (1.6–3.9) 1.9 (1.2–3.1)
Mitotic index
a o10
 4
Grade 1 182 77 (70–85) 1
Grade 2 189 67 (60–74) 1.6 (1.1–2.4)
Grade 3 297 59 (53–65) 2.2 (1.5–3.2)
Clinical response
a 0.15 0.003
X50% 434 67 (63–73) 1 1
o50% 309 64 (58–70) 1.2 (0.9–1.6) 1.5 (1.2–2.0)
HR¼hormonal receptor; LRRFS¼locoregional recurrence-free survival
aFactors entered in the multivariate analysis.
bThe mitotic index was not entered into the model as it was
highly correlated with the histological grade.
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as it is an important part of the treatment of large breast cancers
(Whelan et al, 2000; Clarke et al, 2005) and has been shown to
achieve complete clinical response (6–41%) with doses compatible
with planned secondary surgeries (Calitchi et al, 1991; Scholl et al,
1994; Broet et al, 1999; Bollet et al, 2006). At the Institut Curie,
the S6 trial randomised premenopausal women between
chemotherapy and radiotherapy as an initial treatment for large
breast cancers (Scholl et al, 1994). There was no difference in the
10-year OS (Broet et al, 1999). Out of 69 tumours still palpable
after four cycles of FAC (5-fluorouracil, adriamycine and
cyclophosphamide), 42 (61%) achieved complete clinical
response after 54Gy. In contrast with chemotherapy (Vincent-
Salomon et al, 2004; Andre et al, 2005), which is more effective in
proliferative tumours, the effect of radiotherapy does not seem to
depend on the degree of proliferation (or on the histological
grade) (Remvikos et al, 1993; Rozan et al, 1998; Clarke et al,
2006). Radiotherapy could thus theoretically play a role in
increasing the rate of breast conservation for tumours that fail to
sufficiently shrink with primary chemotherapy because of low
proliferation, as in the case of lobular carcinomas. Another study
performed at the Institut Curie showed a similar rate of
pathological complete response with preoperative concurrent
chemoradiotherapy for lobular and for ductal invasive carcinomas
(31 vs 22%; P¼0.5; Bollet et al, 2006). Ring et al (2003) found,
in a retrospective study comparing surgery (either breast-
conserving or mastectomy) and exclusive radiotherapy for women
who achieved clinical complete responses after primary chemo-
therapy, a nonsignificant trend toward increased locoregional-
only recurrence for the no surgery group. However, they also
found that patients achieving both clinical and ultrasound
complete responses, and not undergoing surgery, had a low (8%)
rate of locoregional recurrence at 5 years. Additionally, MRI has
also proven to be useful in the assessment of the tumour response
to chemotherapy (Thibault et al, 2004; Warren et al, 2004;
Partridge et al, 2005; Segara et al, 2007). This good value of MRI
in the evaluation of tumour response should also apply to ILC as,
even though ILC is still a challenge for MRI (Kinkel and Hylton,
2001), the addition of MRI to mammography still increases the
sensitivity in the detection of ILC (Gilles et al, 1994; Sittek et al,
1998) and, most importantly in the case of the response evaluation,
the volumetric assessment is improved (Boetes et al, 2004; Fabre
Demard et al, 2005; Caramella et al, 2007; Mann et al, 2008). This
raises the question of whether patients who achieve complete
clinical and imaging response could in some cases entirely avoid
surgery. This issue, needless to say, would need to be properly
assessed in a prospective randomised trial. Additionally, to really
benefit from higher rates of breast conservation, one needs to
closely evaluate the cosmetic effects of this therapeutic approach
but which could not be assessed in our study. One particular
concern is indeed that it is associated with worse cosmetic results,
because they deteriorate with the radiotherapy total dose (whole
breastþboost; Vrieling et al, 1999), with chemotherapy (Vass and
Bairati, 2005), and when radiotherapy is given pre- rather than
post-operatively, both in the case of standard (Durand et al, 1987)
or oncoplastic (Clough et al, 2003) surgeries.
In conclusion, our series confirmed that lobular carcinomas
demonstrate a lower response rate to neoadjuvant chemotherapy
than ductal carcinomas, but that in multivariate analysis only
low histological grades remained predictive of poor response to
chemotherapy. The breast conservation in our series was higher
than the one expected from the literature for both histological
types. The most obvious explanation was the frequent use of either
preoperative or exclusive radiotherapy after chemotherapy,
especially for tumours with a poor response to chemotherapy
and therefore for lobular carcinomas. The lobular type had no
adverse effect on locoregional control even in the group of patients
treated with breast conservation. Further studies are still needed to
evaluate the exact role of preoperative/exclusive radiotherapy after
neoadjuvant chemotherapy, not only in terms of efficacy but also
of tolerance and long-term cosmetic effects.
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